Breast Cancer Clinical Trial of Chemotherapy and Trastuzumab: Potential Tool to Identify Cardiac Modifying Variants of Dilated Cardiomyopathy

Doxorubicin and the ERBB2 targeted therapy, trastuzumab, are routinely used in the treatment of HER2+ breast cancer. In mouse models, doxorubicin is known to cause cardiomyopathy and conditional cardiac knock out of Erbb2 results in dilated cardiomyopathy and increased sensitivity to doxorubicin-ind...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Cardiovasc Dev Dis
Autors principals: Serie, Daniel J., Crook, Julia E., Necela, Brian M., Axenfeld, Bianca C., Dockter, Travis J., Colon-Otero, Gerardo, Perez, Edith A., Thompson, E. Aubrey, Norton, Nadine
Format: Artigo
Idioma:Inglês
Publicat: MDPI 2017
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5715703/
https://ncbi.nlm.nih.gov/pubmed/29367538
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcdd4020006
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars